Results 151 to 160 of about 165,320 (303)

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. We studied the incidence, risk factors for, and outcomes of CMV infection after Day + 90 of allogeneic hematopoietic cell transplant (alloHCT ...
George L. Chen   +15 more
wiley   +1 more source

The Operation of Canada's Only Virtually Operated Radiation Oncology Service During the COVID-19 Pandemic. [PDF]

open access: yesAdv Radiat Oncol, 2021
Romani C   +7 more
europepmc   +1 more source

The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic cell transplantation (allo‐HCT) is an effective treatment for patients with high‐risk hematologic malignancies. Over the last decade, gut microbiota composition during allo‐HCT has been associated with patients' outcomes.
Wenjing Hao   +4 more
wiley   +1 more source

Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey

open access: yesCancer Medicine
Purpose Identify factors influencing audiological care for chemotherapy‐induced ototoxicity from the perspectives of oncology providers in the Veterans Health Administration (VA), and quantify audiology service use among Veterans receiving ototoxic ...
Cecilia Lacey   +9 more
doaj   +1 more source

Integration of a patient-centred MUO/CUP service within a new acute oncology service: challenges and rewards. [PDF]

open access: yesFuture Healthc J, 2021
Dasgupta S   +5 more
europepmc   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram   +94 more
wiley   +1 more source

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients.
Nichola Cooper   +17 more
wiley   +1 more source

Top priorities for health service improvements among Australian oncology patients

open access: yes
Objective: To determine among a sample of Australian cancer patients receiving outpatient oncology care: 1) the most frequently endorsed general health service improvements selected by patients; 2) for the three most endorsed general health service ...
Robert Sanson-Fisher (21136211)   +5 more
core  

How to Build a Cardio-Oncology Service? [PDF]

open access: yesEuropean Journal of Heart Failure, 2018
Farmakis, D.   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy